Krystal Biotech (NASDAQ:KRYS) Shares Gap Down – Here’s What Happened

Krystal Biotech, Inc. (NASDAQ:KRYS) gapped down before the market opened on Monday . The stock had previously closed at $341.12, but opened at $320.70. Krystal Biotech shares last traded at $315.6780, with a volume of 155,203 shares traded.

More Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Adjusted earnings exceeded expectations: Krystal reported diluted EPS of $1.79, above the $1.70 consensus estimate and up from $1.29 a year earlier. Net income increased to $54.8 million from $38.3 million. Krystal Biotech Q2 earnings report
• Positive Sentiment: VYJUVEK demand remained strong: Second-quarter product revenue rose 24% year over year to $119.2 million, supported by more than 730 reimbursement approvals and over 640 prescribers. The company is also on track to launch VYJUVEK in Spain and Italy before year-end. Krystal Biotech second-quarter results
• Positive Sentiment: Pipeline catalysts are approaching: Krystal expects multiple clinical readouts in the second half of 2026, including fourth-quarter data for KB803 in corneal abrasions. It ended the quarter with approximately $1.1 billion in cash and investments, supporting continued development.
• Positive Sentiment: HC Wainwright raised its earnings forecasts for 2026, 2027 and 2028 and maintained a Buy rating with a $361 price target, citing improved longer-term earnings potential. HC Wainwright estimates
• Negative Sentiment: Revenue narrowly missed expectations: Quarterly revenue of $119.2 million was below the approximately $120.9 million consensus forecast. That miss appears to have outweighed the EPS beat in the initial market reaction. Krystal shares slide after earnings
• Negative Sentiment: Spending and execution risks remain: 2026 non-GAAP R&D and SG&A expenses are expected to total $175 million-$195 million. European pricing and reimbursement negotiations could also delay revenue growth in Germany and France.

Wall Street Analyst Weigh In

KRYS has been the subject of a number of research reports. TD Cowen increased their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Evercore reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Citigroup upped their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Bank of America raised their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $361.56.

Krystal Biotech Stock Performance

The firm has a market cap of $9.57 billion, a price-to-earnings ratio of 43.42 and a beta of 0.53. The stock has a 50-day moving average of $340.40 and a 200-day moving average of $296.82.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The firm had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. Sell-side analysts predict that Krystal Biotech, Inc. will post 7.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 26,642 shares of company stock valued at $8,243,923. 13.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of KRYS. USA Financial Formulas acquired a new position in shares of Krystal Biotech during the 1st quarter worth approximately $44,000. Summit Global Investments bought a new position in shares of Krystal Biotech in the second quarter valued at $805,000. Oppenheimer Asset Management Inc. bought a new position in shares of Krystal Biotech in the second quarter valued at $259,000. Hennion & Walsh Asset Management Inc. acquired a new position in Krystal Biotech during the second quarter worth $337,000. Finally, GAMMA Investing LLC increased its holdings in Krystal Biotech by 16.3% during the second quarter. GAMMA Investing LLC now owns 998 shares of the company’s stock worth $371,000 after buying an additional 140 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.